Article Sidebar
Views pdf: 57
ASSESSMENT OF ANXIETY AND DEPRESSION DISORDERS IN PATIENTS WITH PERSISTENT REFLUX SYMPTOMS
Main Article Content
Abstract
Objective: To evaluate the proportion of anxiety and depression in patients with persistent reflux symptoms and to preliminarily evaluate some related factors. Methods: A cross-sectional study was conducted on 58 patients with persistent reflux symptoms (no response to 8 weeks of PPI therapy) at the Institute of Gastroenterology and Hepatology from December 2022 to July 2024. Anxiety and depression were assessed using the DASS-21 scale. Results: The mean age was 47.3±14.1, 63.8% were female. The proportion of patients with at least one typical symptom was (94.8%). The rates of GERD, functional heartburn, and reflux hypersensitive were 27.6%, 53.5%, and 18.9%, respectively. 51.7% and 25.9% of patients reported anxiety and depression, respectively. The rates of anxiety and depression were statistically significantly higher in female patients than in male patients (p=0.013 and p=0.049). The functional heartburn group had the highest prevalence of anxiety disorder (67.7%), followed by the GERD group (37.5%) and the lowest in the reflux hypersensitive group (27.3%). The highest rate of depression was recorded in the GERD group (43.8%). However, this difference was not statistically significant (p>0.05). Conclusion: There was no statistically significant difference in the prevalence of anxiety and depression among the patient groups diagnosed based on 24-hour pH-impedance monitoring.
Article Details
Keywords
Gastroesophageal Reflux Disease, GERD, anxiety, depression, DASS-21
References
2. van der Velden A.W., de Wit N.J., et al. (2008), "Maintenance Treatment for GERD: Residual Symptoms Are Associated with Psychological Distress", Digestion, 77(3-4), pp. 207-213.
3. Vuong Duong Anh, Van Ginneken Ewout, et al. (2011), "Mental health in Vietnam: Burden of disease and availability of services", Asian Journal of Psychiatry, 4(1), pp. 65-70.
4. El-Serag H., Becher A., et al. (2010), "Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies", Aliment Pharmacol Ther, 32(6), pp. 720-37.
5. Gyawali C. P., Yadlapati R., et al. (2024), "Updates to the modern diagnosis of GERD: Lyon consensus 2.0", Gut, 73(2), pp. 361-371.
6. Lee Y. S., Jang B. H., et al. (2018), "Comorbid risks of psychological disorders and gastroesophageal reflux disorder using the national health insurance service-National Sample Cohort: A STROBE-compliant article", Medicine (Baltimore), 97(18), pp. e0153.
7. Mizyed I., Fass S. S., et al. (2009), "Review article: gastro-oesophageal reflux disease and psychological comorbidity", Aliment Pharmacol Ther, 29(4), pp. 351-8.
8. Nojkov B., Rubenstein J. H., et al. (2008), "The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease", Aliment Pharmacol Ther, 27(6), pp. 473-82.
9. Yadlapati R., Gyawali C. P., et al. (2022), "AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review", Clin Gastroenterol Hepatol, 20(5), pp. 984-994.e1.
10. Zerbib F., Bredenoord A. J., et al. (2021), "ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease", Neurogastroenterol Motil, 33(4), pp. e14075.